Background: Low-density lipoprotein cholesterol (LDL-C) concentrations are the primary therapeutic target in patients with atherosclerotic cardiovascular disease (ASCVD). However, at low LDL-C concentrations, there is a significant underestimation using the Friedewald equation compared with ultracentrifugation.
Recent guidelines have recommended a 50% reduction in LDL-cholesterol (LDL-C) concentrations, or an LDL-C goal of less than 70 mg per dL, in patients at highest risk for atherosclerotic cardiovascular disease (ASCVD). 1 It has been documented that the Friedewald equation underestimates LDL-C at low levels compared with ultracentrifugation methods. 2, 3 However, these studies did not compare the Friedewald calculation with the more readily available homogenous assays that measure LDL-C directly.
In a different article, one of us recently discussed challenges in the measurement and reporting of LDL-C concentrations. 4 Although ultracentrifugation is desirable for quantification of LDL-C, it is a tedious, labor intensive assay and is restricted to selective laboratories. 4 The novel formula proposed by
Martin et al 2 in a large cohort is equivalent to the LDL-C values obtained by the vertical auto profile (VAP), which is similar to the criterion standard, namely, ultracentrifugation. 4 Direct homogenous assays for LDL-C are more readily available in most clinical laboratories and are a reflex measurement when plasma triglyceride levels are less than 400 mg per dL and when the patient is not fasting; those assays are more cost effective than beta-quantification. 4 The
College of American Pathology (CAP) proficiency data indicate that 2564 laboratories perform the LDL-direct assay and 3000 laboratories perform LDL-calculated assays. 5 This suggests that 85.5% of laboratories can report a direct LDL-C result and also that the assay is standardized compared with the LDL-N process.
In this pilot study, we compared LDL-C results obtained using the Friedewald equation (LDL-F) with those obtained by a direct homogenous LDL (LDL-D) assay, as well as the novel formula (LDL-N) proposed by Martin et al 2 in an adult population sample because of the greater risk for ASCVD in adults. Also, we undertook this comparison in patient specimens with triglyceride levels between 200 mg per dL and 399 mg per dL and LDL-F of less than 100 mg per dL because we believe that the problem will manifest most strongly in these patient specimens.
Materials and Methods
We submitted the protocol for this study to the University of California, Davis (UC Davis) institutional review board (IRB). This study was waived for full IRB consideration by the IRB director based on the use of masked specimens and the use of assays with United States Food and Drug Administration (FDA) approval. Every day, the medical technologist (M.I.) collected all specimens with an LDL-F value of less than 100 mg per dL and performed a LDL-D on those specimens. He created a spreadsheet with the age, sex, and lipid profiles, including LDL-D, for the donors of all 152 consecutive specimens he received and provided coauthor Jialal with a spreadsheet of this information on completion of specimen collection.
Lipid profiles were measured on specimens from donors who had been fasting at the time of donation. We measured cholesterol and triglycerides via enzymatic assay on the Beckman Synchron instrument (Beckman Coulter, Inc) and measured direct HDL cholesterol using a homogenous assay on the same instrument. Because all specimens had a TG value of less than 400 mg per dL, we calculated LDL-C using the Friedewald equation from the measure of total cholesterol, HDL-C, and triglycerides. 4 In all specimens with LDL-F of less than 100 mg per dL, LDL-C was also measured via the LDL-D assay on the Beckman Synchron instrument.
This process uses detergents to solubilize and mask all nonlow-density lipoprotein (LDL) particles using a 2-reagent system. The LDL-C derived from the novel formula was calculated from non-HDL-C and TG as described by Martin et al 2 using an adjustable factor from a 180-celldefined strata. Briefly, LDL-N was calculated as [non-HDL-C]-[triglycerides/AF], where AF is an adjustable factor in the 180-cell table described by Martin et al. 2 The intra-and interassay coefficient of variation (CV) for total cholesterol, triglycerides, and HDL-C were all less than 3% and 4.5%, respectively. For the direct LDL assay, the intra-and interassay CVs were less than 2% and 3%, respectively.
Data are presented as mean (SD). We undertook statistical comparisons using Graph Pad Prism. Correlation of the LDL-F and LDL-D with the LDL-N was assessed using an EP evaluator. Misclassification rates were assessed for LDL-F at values of less than 100 mg per dL and values of less than 70 mg per dL, respectively, based on the LDL-D values.
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Results
We studied 152 consecutive patient specimens with LDL-C of less than 100 mg per dL calculated using the Friedewald equation; the specimens had triglyceride levels ranging from 200 mg per dL through 399 mg per dL. The mean age of the patients was 59 years, and the male to female ratio was 80:72. The total mean (SD) cholesterol, triglycerides, and HDL-cholesterol concentrations were 166 (25) The most significant differences were observed with patients with reported LDL-C levels less than 70 mg per dL based upon the Friedewald calculation (n ¼ 59): LDL-F versus LDL-D; mean (SD) of 45 (15) mg per dL versus 59 (10) mg per dL (P <.001). There was a negative bias of 27% for the LDL-F value compared with the LDL-D value ( Figure 1B ).
When the LDL-F value was compared with the LDL-N value, there was a significant negative bias for concentrations ranging from 70 mg per dL through 99 mg per dL: 17% negative bias, P <.001. For LDL-C concentrations less than 70 mg per dL, the negative bias was 36%, P <.001. These data are depicted in Figure 2 . Finally, as shown in Figure 3 , the percentage negative bias values were 2% and 1% for the LDL-C concentrations of 70 mg per dL and 99 mg per dL and less than 70 mg per dL, respectively. Using the LDL-D as a standard, we computed misclassification rates for the LDL-F values for concentrations less than 70 mg per dL and 70 mg per dL to 99 mg per dL and found them to be 49% and 34%, respectively.
Discussion
In this preliminary report, we confirm, using a direct-LDL-C assay, that to attain the targets for patients at greatest risk for ASCVD (those with multiple risk factors or with current ASCVD), using the Friedewald equation calculate LDL-C is misleading and underestimates LDL-C, as reported previously using ultracentrifugation. 2, 3 This finding has the potential to lull healthcare professionals into a false sense of security that specimens from their patients are at the desired goal values. The issue remains true whether one uses targets of LDL-C of less than 100 mg per dL or less than 70 mg per dL, or percentage LDL-C reduction of greater than 50% or 30% to 50%. This problem is particularly relevant in patients with plasma triglyceride values in the range of 200 mg per dL to 399 mg per dL, when laboratories use the calculated LDL-F rather than the LDL-D assay to measure LDL-C levels.
Although using beta-quantification to report LDL-C would be most accurate, 2,3 this method is cumbersome, labor-intensive, and requires a dedicated ultracentrifuge 6 ; as a result, it is not available in most clinical laboratories, to our knowledge. Also, the LDL-C is obtained by subtracting the HDL-C from the infranatant total cholesterol value after ultracentrifugation rather than being directly assayed. Although both groups showed a significant underestimation of LDL-C by the Friedewald equation compared with ultracentrifugation, we did not undertake that comparison. Instead, we focused on the LDL-D assay as our reference standard. This action could be perceived as a weakness of our pilot study.
Many have sought to improve on the Friedewald equation, as reported by Martin et al. 2 However, that research group uses a novel formula involving a calculation based on non-HDL and TG values and is not easily applicable to clinical laboratories, given the adjustable factor that needs to be derived from the 180-strata table and thus is not easy to automate. Further, it is affected by high triglyceride levels and, hence, fasting; it has not been validated in a large clinical trial. Also, unlike LDL-D, it has not entered the mainstream of laboratory medicine and is not part of CAP surveys.
One of us has previously shown that the direct LDL-C assay is reliable in the entire range of triglycerides up to values of 1000 mg per dL. 6 In that study, 32% of the 156 specimens had triglyceride levels of less than 400 mg per dL and less than 1000 mg per dL. LDL-C levels determined by beta quantification showed excellent concordance for LDL-C values less than 130 mg per dL, which is an accepted target at that point in the assessment of ASCVD risk. In addition, we have confirmed the validity of the direct LDL-C assay compared with beta-quantification in specimens from patients with diabetes, another group at high risk for ASCVD. 7 A critical review on this topic also supported the validity of the direct LDL-C assay compared with betaquantification. 8 Hence, we suggest using the direct LDL-C assay for reporting LDL-C in patients with triglyceride levels between 200 mg per dL and 399 mg per dL and LDL-C levels less than 100 mg per dL. These findings appear to be particularly important for patients with LDL-C values of less than 70 mg per dL, which would result in more reliable measurements to guide patient care. In fact, the direct LDL-C assay has been used in statin trials such as the Heart Protection Study, the largest statin trial in the literature, involving 20,536 patients, in which lowering of the LDL-C by means of statin therapy was shown to reduce cardiovascular events and mortality. 9 In our pilot study, the misclassification rates of LDL-F for our 2 subgroups (ie, LDL-C <70 mg/dL and LDL-C 70 mg/dL-99 mg/dL were 49% and 34%, respectively. Hence, these rates appear to be a serious problem in the patients at highest risk for ASCVD and need to be confirmed by other groups using larger sample sizes because it could have major implications for reporting LDL-C concentrations in the clinical laboratory.
We believe that the novel formula proposed by Martin et al 2 clearly has merit; its advantage over the LDL-F was confirmed in our report. However, this advantage needs to be validated in large statin trials. Until then, for this group of patient specimens with LDL-C values less than 100 mg per dL and triglyceride levels between 200 mg per dL and 399 mg per dL, we favor the direct LDL assay. A drawback of the direct LDL-C assay is that there are concerns regarding its accuracy in patients with liver disease, kidney disease, and familial dyslipidemias. However, we believe these are minor issues compared with the underestimation of LDL-C using the Friedewald equation, which also results in inaccuracies in these illness groups. 4 Also, certain recently FDA-approved proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors can lower the LDL-C level beyond the and requires a dedicated ultracentrifuge 6 ; as a result, it is not available in most clinical laboratories, to our knowledge. Also, the LDL-C is obtained by subtracting the HDL-C from the infranatant total cholesterol value after ultracentrifugation rather than being directly assayed. Although both groups showed a significant underestimation of LDL-C by the Friedewald equation compared with ultracentrifugation, we did not undertake that comparison. Instead, we focused on the LDL-D assay as our reference standard. This action could be perceived as a weakness of our pilot study.
We believe that the novel formula proposed by Martin et al 2 clearly has merit; its advantage over the LDL-F was confirmed in our report. However, this advantage needs to be validated in large statin trials. Until then, for this group of patient specimens with LDL-C values less than 100 mg per dL and triglyceride levels between 200 mg per dL and 399 mg per dL, we favor the direct LDL assay. A drawback of the direct LDL-C assay is that there are concerns regarding its accuracy in patients with liver disease, kidney disease, and familial dyslipidemias. However, we believe these are minor issues compared with the underestimation of LDL-C using the Friedewald equation, which also results in inaccuracies in these illness groups. 4 Also, certain recently FDA-approved proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors can lower the LDL-C level beyond the www.labmedicine.commaximum tolerated statin dose by approximately 60%, to levels approaching 30 mg per dL. 10 The availability of these novel agents underscores the need to provide reliable LDL-C reporting by using the direct LDL-C homogenous assays if beta-quantification is unavailable because the Friedewald equation is inaccurate in patients with such low LDL-C concentrations. Thus, in the spirit of providing optimum laboratory support for ASCVD, we need to consider the novel LDL-C assay formula and the direct LDL assays as part of our repertoire of tests when reporting low LDL-C levels. From our data we favor the direct-LDL-C assays as laboratory professionals, based on the reasons provided herein. LM
